Ionis Pharmaceuticals Inc. (IONS) saw an uptrend of 4.23% in the recent, registering $47.58 being its most recent bid. The distance of current price level is -28.15% lower than the highest price of $66.22 marked by the stock while trading over the past 52-weeks, whereas it is 21.01% higher than the lowest price of $39.32 the company dropped to over past 52-weeks. The latest news story on IONS appeared in Zacks under the title “Ionis’ Alexander Disease Candidate Gets Orphan Drug Status” on Oct-02-20.
Squeezing the time span to 30 day period shows us the stock currently buoying -13.36% below one month high and is +5.45% above of the lowest during that time. Looking into the simple moving average, Ionis Pharmaceuticals Inc. (IONS)’s stock is currently standing at a SMA-50 of $53.14 while that of 5-day is reading $47.38.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and IONS’s SMA-200 at this time is reading $55.73.
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Ionis Pharmaceuticals Inc. (IONS) releasing its most recent results for the quarter ended 6/29/2020 posted a surprise factor of 14.80% for net revenue. During the reported three-month period, company’s sales were $145.54 billion while analysts on average were estimating the same to be $188.67 million.
Looking into the perspective of Ionis Pharmaceuticals Inc. (NASDAQ:IONS)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.27 for stock’s EPS in the current quarter. Company’s EPS for the last quarter was -0.23.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). Institutions currently hold 139.35 million of IONS’s outstanding shares. That indicates a holding of about 87.93% or $25027.08 of worth by institutional holders in the company.
Moreover, the latest SEC filings also revealed that stock came across 8 new insider purchases involving 23,140 shares. On the other hand, IONS declared 134,228 shares have been sold in 11 insider transactions over the past three months.
As on Jun 29, 2020, FMR, LLC was the top most holder in Ionis Pharmaceuticals Inc. (NASDAQ:IONS) with an ownership of 20.81 million shares of the company or 14.90% of the stake worth $1.23 billion. The filing also reveals Vanguard Group, Inc. (The) as the second largest holder in the company with a control over 8.81% of the stake or worth of $725.58 million for having 12.31 million shares in hand.
Blackrock Inc. also came increasing its position in the company during the recent quarter and it now holds 6.19% of the outstanding shares. With this there are now 526 institutions which have been in possession of IONS’s shares.
Investors are for sure keenly observing the recommendations of analysts at Wall Street about the Ionis Pharmaceuticals Inc. And review of current evaluations agreed by the analysts discloses a Buy rating for IONS. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.60 for the stock. Lower value of between 1 and 2 implies a Buy recommendation whereas the value in the range of above 4 suggests Hold while below 1 recommends the investors to Sell the stock. Currently, the stock has been recommended as Moderate Buy by 23 of the Wall Street analysts.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, liquidity recorded by Ionis Pharmaceuticals Inc. was 9.97 while posting a debt to equity ratio of 0.59. The count was 53.40 for long-term debt to equity ratio.
Company attained a return on equity (ROE) of 9.40% in past 12 months against the same posted by peer companies of the relevant industry. The rising figure indicates that IONS came strengthening itself from within over the past one year. A comparison of company’s ROE with that of the Biotechnology industry and with the broader scale at the Healthcare sector level shows that industry’s average ROE is -46.92.
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term average volume of a stock is an effective way to make use of. When looking into those indicators for Ionis Pharmaceuticals Inc. (IONS), we notice that the stock’s 20-day average volume is at 1,177,745 shares and 100% of that short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 100% are spotting the stock at Sell with its 50-day average volume of 872,128 shares. And to end with, IONS’s 100-day average volume are 833,992 shares with 50% of the long-term indicators pointing towards Sell for the stock.